Drugs / PLD
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07109414 | Dec 2025 → Oct 2028 expected | refractory malignant neoplasm | Novita Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLD | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07109414 ↗ |
| Route | Intravenous | “PLD will be provided as an infusion via intravenous route of administration in the study.” NCT07109414 ↗ |